Why the study?
The 2026 ESC guidelines removed HF with mildly reduced ejection fraction as a clinical entity to recognize two phenotypes—HFrEF (LVEF < 50%) and HFpEF (LVEF ≥ 50%)—necessitating an integration of the updated guidelines with pivotal randomized evidence across the ejection fraction spectrum, including the frequently under-recognized trajectory of HFimpEF.
Population
Patients with heart failure across the ejection fraction spectrum, including HFrEF, HFpEF, and HFimpEF
Design
Narrative review
Answers are grounded in this paper and cite their sources.
May support phenotype-directed rapid titration in HF per 2026 ESC guidelines; leaves open prospective validation across LVEF phenotypes.
Heart failure (HF) management has moved beyond a single ejection fraction threshold toward rapid implementation of outcome-modifying therapy, active decongestion, and phenotype-directed care. The 2026 European Society of Cardiology (ESC) guidelines removed HF with mildly reduced ejection fraction as a clinical entity and recognize two phenotypes: HF with reduced ejection fraction (HFrEF; left ventricular ejection fraction [LVEF] < 50%) and HF with preserved ejection fraction (HFpEF; LVEF ≥ 50%). This narrative review integrates the guidelines with pivotal randomized evidence from prevention to advanced HF. In HFrEF, the goal is early exposure to all four foundational classes—renin–angiotensin system or angiotensin receptor–neprilysin inhibition, beta-blockade, mineralocorticoid receptor antagonism, and sodium–glucose cotransporter 2 inhibition—with titration every 1–2 weeks; this framework extends to an LVEF of 41–49%, although evidence for some classes there derives from subgroup and pooled analyses. Patients whose LVEF improves (HFimpEF), a frequently under-recognized trajectory, remain on the HFrEF pathway and require continued foundational therapy and structured surveillance. In HFpEF, sodium–glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists form the foundation, while semaglutide and tirzepatide improve health status and exercise capacity in obesity-related HFpEF, with fewer worsening-HF events also demonstrated for tirzepatide. Because most trials used earlier LVEF categories, each is interpreted within its original population. The greatest remaining opportunity is closing the implementation gap through structured titration and multidisciplinary follow-up.
No takes yet. Share an insight, caveat, or question.
Craciun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: